Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 11,881 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $26.53, for a total value of $315,202.93. Following the transaction, the chief operating officer owned 377,802 shares in the company, valued at approximately $10,023,087.06. This trade represents a 3.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Friday, October 30th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.73, for a total value of $317,579.13.
- On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.47, for a total value of $302,609.07.
- On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $28.45, for a total value of $338,014.45.
- On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $26.04, for a total value of $309,381.24.
- On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.98, for a total transaction of $296,787.38.
- On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.05, for a total transaction of $285,738.05.
- On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.41, for a total transaction of $301,896.21.
- On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.61, for a total transaction of $304,272.41.
- On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.50, for a total transaction of $302,965.50.
- On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.66, for a total transaction of $304,866.46.
Adaptive Biotechnologies Price Performance
NASDAQ:ADPT traded up $1.15 during trading hours on Friday, hitting $27.98. 3,333,510 shares of the company were exchanged, compared to its average volume of 2,050,401. Adaptive Biotechnologies Corporation has a 52-week low of $12.00 and a 52-week high of $30.74. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. The company’s 50 day moving average price is $26.42 and its 200-day moving average price is $19.86.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.12. The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $71.57 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. Adaptive Biotechnologies’s revenue for the quarter was down 10.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.06 EPS. As a group, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.40 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts recently issued reports on the company. National Bank Financial set a $34.00 target price on Adaptive Biotechnologies in a research report on Tuesday, September 22nd. Guggenheim lifted their price target on Adaptive Biotechnologies from $25.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Morgan Stanley boosted their price target on Adaptive Biotechnologies from $22.00 to $27.00 and gave the company an “equal weight” rating in a research note on Monday, October 12th. BTIG Research boosted their price target on Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. Finally, Piper Sandler increased their price objective on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $30.06.
Check Out Our Latest Report on ADPT
Institutional Trading of Adaptive Biotechnologies
A number of hedge funds have recently modified their holdings of ADPT. Russell Investments Group Ltd. grew its holdings in Adaptive Biotechnologies by 14.0% during the third quarter. Russell Investments Group Ltd. now owns 89,721 shares of the company’s stock worth $2,593,000 after acquiring an additional 10,999 shares during the period. Mesirow Financial Investment Management Inc. purchased a new position in Adaptive Biotechnologies during the third quarter valued at approximately $252,000. University of Texas Texas AM Investment Management Co. acquired a new position in Adaptive Biotechnologies in the third quarter valued at approximately $277,000. Ethic Inc. acquired a new position in Adaptive Biotechnologies in the third quarter valued at approximately $244,000. Finally, Pictet Asset Management Holding SA lifted its holdings in Adaptive Biotechnologies by 12.5% in the third quarter. Pictet Asset Management Holding SA now owns 17,924 shares of the company’s stock valued at $518,000 after acquiring an additional 1,985 shares during the period. Hedge funds and other institutional investors own 99.17% of the company’s stock.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.
Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.
Featured Articles
- Five stocks we like better than Adaptive Biotechnologies
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
